Scientist Home Future Health Ltd. (SHFH) reported nine-month revenue of $485,043 for the period ended September 30, 2026, up 318.2% from $115,980 a year earlier. Retail trading contributed $474,779 and services $10,264. Third-quarter revenue was $211,984 and net income was $8,212, compared with $39,604 revenue and a $47,845 net loss in the 2025 quarter.
For the first nine months, SHFH recorded a $191,712 net loss, versus a $78,999 loss a year earlier, and net cash used in operating activities was $129,233. Cash as of September 30 was $13,653, which management said provided less than one month of operational cash runway; the working capital deficit was $198,046. A $198,574 non-trade balance due to related party B is repayable on demand. Management estimated a $255,600 projected cash outflow and working capital funding gap over the next 12 months, and said its plans do not alleviate substantial doubt about SHFH's ability to continue as a going concern.
Scientist Home Future Health Limited, a Nevada holding company operating health supplement retail and check-up services in Hong Kong, reported for the six months ended June 30, 2026 revenue of $273,059, up from $76,376 a year earlier. Retail product sales contributed $265,156 and services $7,903.
The company posted a significantly larger net loss of $199,924 versus $31,154 in 2025, driven by higher selling, general and administrative expenses of $288,101. Cash fell to $9,047, with total assets of $529,844 and current liabilities of $340,299, resulting in net current liabilities of $214,975 and negative stockholders’ equity of $86,324.
Management and the auditor state that these losses, the working capital deficit and accumulated deficit raise substantial doubt about the company’s ability to continue as a going concern. Operations are funded by related‑party and director advances, and 100% of cost of revenues comes from a single related‑party vendor. Management also reports material weaknesses in internal control over financial reporting, including lack of segregation of duties and no independent board or audit committee.
Scientist Home Future Health Limited reported quarterly results for the three months ended March 31, 2026, showing rapid growth but rising losses. Revenue reached $188,756, mainly from retail sales of health supplements and topical creams, compared with $44,824 a year earlier. Higher salaries, rent, advertising, and professional fees pushed selling, general and administrative expenses to $161,140, leading to a net loss of $102,072 versus prior net income of $6,059. Cash fell to $15,332, total assets were $558,759, and stockholders’ equity declined to $11,427, close to the total liabilities of $547,332. Management and the auditor highlight substantial doubt about the company’s ability to continue as a going concern, citing recurring losses, net current liabilities of $120,220, dependence on related-party financing, and the need for additional shareholder support or external funding.
Scientist Home Future Health Limited reported its first full year of operations with 2025 revenue of $204,055, mainly from retail sales of health supplements and topical creams, plus physical check-up services. Despite this growth from 2024’s $120,775, the company posted a net loss of $231,725, reflecting high rental, professional and start-up operating expenses.
At December 31, 2025, cash was $68,888 against current liabilities of $214,458, resulting in net current liabilities of $22,212 and an accumulated deficit of $246,705. Both management and the auditor concluded these conditions raise substantial doubt about the company’s ability to continue as a going concern. The business relies heavily on related parties for product supply, office leases and funding, while the CEO controls about 84% of the 23,716,000 outstanding shares.
The stock is quoted on the OTC market under symbol SHFH and is likely to be treated as a penny stock, which may limit trading liquidity. Internal controls over financial reporting are described as ineffective due to lack of segregation of duties, absence of an independent board or audit committee, and missing formal control documentation.